Two-year outcome of vagus nerve stimulation in treatment-resistant depression

Journal of Clinical Psychopharmacology

Volumn 30, Issue 3, 2010, Pages 273-281

  Bajbouj, Malek ^a,b   Merkl, Angela ^b   Schlaepfer, Thomas E ^c,d,e,f   Frick, Caroline ^c   Zobel, Astrid ^c   Maier, Wolfgang ^c   O'Keane, Veronica ^g   Corcoran, Ciaran ^g   Adolfsson, Rolf ^h   Trimble, Michael ⁱ   Rau, Harald ^j   Hoff, Hans Joachim ^j   Padberg, Frank ^k   Müller Siecheneder, Florian ^k   Audenaert, Kurt ^l   Van Den Abbeele, Dirk ^l   Matthews, Keith ^m   Christmas, David ^m   Eljamel, Sam ^m   Heuser, Isabella ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

^e Departments of Psychiatry   (Australia)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g ST JAMES S HOSPITAL   (Ireland)

^h UMEÅ UNIVERSITY HOSPITAL   (Sweden)

ⁱ NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^j EVANGELISCHES KRANKENHAUS   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l GHENT UNIVERSITY HOSPITAL   (Belgium)

^m UNIVERSITY OF DUNDEE   (United Kingdom)

more..

Author keywords

Clinical trial; Depression; Hamilton Rating Scale for Depression; Major depressive disorder; Vagus nerve stimulation

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DYSPHONIA; EUROPE; FEMALE; HAMILTON SCALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PAIN; PATIENT SAFETY; PRIORITY JOURNAL; REMISSION; SUICIDE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VAGUS NERVE STIMULATION;

ADULT; AGED; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; ELECTRIC STIMULATION THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; VAGUS NERVE STIMULATION; YOUNG ADULT;

EID: 77952330742     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181db8831     Document Type: Article

References (27)

1. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):10-17.
2. Sackeim HA, Prudic J, Devanand DP, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry. 2000;57:425-434.
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163: 1905-1917.
4. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31:1841-1853.
5. Carpenter LL. Neurostimulation in resistant depression. J Psychopharmacol. 2006;20:35-40.
6. Henry TR, Bakay RA, Pennell PB, et al. Brain blood-flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: II. Prolonged effects at high and low levels of stimulation. Epilepsia. 2004;45:1064-1070.
7. Daban C, Martinez-Aran A, Cruz N, et al. Safety and efficacy of vagus nerve stimulation in treatment-resistant depression. A systematic review. J Affect Disord. 2008;110:1-15.
8. Rush AJ, Sackeim HA, Marangell LB, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005;58:355-363.
9. Nahas Z, Marangell LB, Husain MM, et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry. 2005;66:1097-1104.
10. George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005;58: 364-373.
11. Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005;58:347-354.
12. Schlaepfer TE, Frick C, Zobel A, et al. Vagus nerve stimulation for depression: efficacy and safety in a European study. Psychol Med. 2008;38:651-661.
13. Prudic J, Haskett RF, Mulsant KM. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry. 1996;153:985-992.
14. Khan A, Redding N, Brown WA. The persistence of the placebo response in antidepressant clinical trials. J Psychiatr Res. 2008;42:791-796.
15. Brown WA, Johnson MF, Chen MG. Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Res. 1992;41:203-214.
16. Quitkin FM, Rabkin JD, Markowitz JM, et al. Use of pattern analysis to identify true drug response. A replication. Arch Gen Psychiatry. 1987;44:259-264.
17. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry. 1986;143:18-23.
18. Hirschfeld RM, Dunner DL, Keitner G, et al. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry. 2002;51:123-133.
19. Fava GA, Fabbri S, Sonino N. Residual symptoms in depression: an emerging therapeutic target. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1019-1027. (Pubitemid 35256092)
20. Koran LM, Gelenberg AJ, Kornstein SG, et al. Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord. 2001;65:27-36.
21. Prudic J, Olfson M, Marcus SC, et al. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry. 2004;55:301-312. (Pubitemid 38117168)
22. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105:164-172.
23. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
24. Papakostas GI, Petersen T, Pava J, et al. Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome. J Nerv Ment Dis. 2003; 191:444-449.
25. Khan A, Khan S, Kolts R, et al. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160:790-792.
26. Prakash A, Risser RC, Mallinckrodt CH. The impact of analytic method on interpretation of outcomes in longitudinal clinical trials. Int J Clin Pract. 2008;62:1147-1158.
27. Siddiqui O, Hung HM, O'Neill R. MMRM vs LOCF: a comprehensive comparison based on simulation study and 25 MDA datasets. J Biopharm Stat. 2009;19:227-246.